Literature DB >> 17531785

Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.

Eric C Santos, Jolynn Sessions, Don Hutcherson, Christopher Flowers, Amelia Langston, Edmund K Waller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17531785     DOI： 10.1016/j.bbmt.2007.02.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  3 in total

1.  High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.

Authors:  Andrew A Lane; Steven L McAfee; Joanne Kennedy; Christine Dube; Eyal C Attar; Karen K Ballen; Bimalangshu R Dey; Thomas R Spitzer; Yi-Bin Chen
Journal:  Leuk Lymphoma       Date:  2011-05-25

2.  Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.

Authors:  Anna Colpo; Ephraim Hochberg; Yi-Bin Chen
Journal:  Oncologist       Date:  2011-12-30

3.  Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

Authors:  Christopher R Flowers; Luciano J Costa; Marcelo C Pasquini; Jennifer Le-Rademacher; Michael Lill; Tsiporah B Shore; William Vaughan; Michael Craig; Cesar O Freytes; Thomas C Shea; Mitchell E Horwitz; Joseph W Fay; Shin Mineishi; Damiano Rondelli; James Mason; Ira Braunschweig; Weiyun Ai; Rosa F Yeh; Tulio E Rodriguez; Ian Flinn; Terrance Comeau; Andrew M Yeager; Michael A Pulsipher; Isabelle Bence-Bruckler; Pierre Laneuville; Philip Bierman; Andy I Chen; Kazunobu Kato; Yanlin Wang; Cong Xu; Angela J Smith; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-31       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.